Matthias Ritgen

Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial

Michael Hallek, Kirsten Fischer, Guenter Fingerle-Rowson et al. · The Lancet · 2010 · 1.9K citations

Medicine, Oncology, Pharmacotherapy +10

Obinutuzumab plus Chlorambucil in Patients with CLL and Coexisting Conditions

Valentin Goede, Kirsten Fischer, Raymonde Busch et al. · New England Journal of Medicine · 2014 · 1.5K citations · Full text

Pharmacy, Hematology, Pharmacotherapy +16

Mutations driving CLL and their evolution in progression and relapse

Dan A. Landau, Eugen Tausch, Amaro Taylor‐Weiner et al. · Nature · 2015 · 1.1K citations · Full text

Medicine, Genetics, Molecular Genetics +10

Venetoclax and Obinutuzumab in Patients with CLL and Coexisting Conditions

Kirsten Fischer, Othman Al‐Sawaf, Jasmin Bahlo et al. · New England Journal of Medicine · 2019 · 852 citations

Pharmacy, Pharmacology, Pharmacotherapy +14

Clinical significance of minimal residual disease quantification in adult patients with standard-risk acute lymphoblastic leukemia

Monika Brüggemann, Thorsten Raff, Thomas Flohr et al. · Blood · 2005 · 537 citations

Medicine, Hematology, Oncology +16